A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Phase 2/3 Recruiting
660 enrolled
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Phase 3 Recruiting
440 enrolled
A Study of Daratumumab
Phase 3 Recruiting
500 enrolled
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Phase 1 Recruiting
140 enrolled
MajesTEC-7
Phase 3 Recruiting
1,590 enrolled
DURGA-4
Phase 3 Recruiting
508 enrolled
Iber-KDd
Phase 2 Recruiting
30 enrolled
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Phase NA Recruiting
41 enrolled
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Phase 2 Recruiting
20 enrolled
MagnetisMM-6
Phase 3 Recruiting
1,116 enrolled
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Phase 3 Recruiting
288 enrolled
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 Recruiting
1,450 enrolled
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Phase 2 Recruiting
20 enrolled
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Phase 1/2 Recruiting
130 enrolled
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Phase 1/2 Recruiting
246 enrolled
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Phase 1/2 Recruiting
440 enrolled
MAGNETISMM-5
Phase 3 Recruiting
944 enrolled
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Phase 3 Recruiting
1,000 enrolled
FASTER
Phase 2 Recruiting
100 enrolled
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Phase 1 Recruiting
317 enrolled
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Phase 2 Recruiting
96 enrolled
MASTER-2
Phase 2 Recruiting
300 enrolled
DREAMM-10
Phase 3 Recruiting
520 enrolled
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Phase 2 Recruiting
40 enrolled
HD10/DSMMXX
Phase 2 Recruiting
160 enrolled
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Phase 1 Recruiting
100 enrolled
STOMP
Phase 1/2 Recruiting
300 enrolled